Crinetics Pharmaceuticals Inc.
Somatostatin agonists to treat acromegaly
This article was originally published in Start Up
The founders of Crinetics Pharmaceuticals Inc. aim to treat endocrine-related diseases and cancers with novel molecules that target peptide hormone receptors. It has been working intensively to apply the concept of biased agonism to the large and popular class of drug targets known as G-protein coupled receptors; it will initially seek to develop a treatment for acromegaly.